FDA Revises Biomarker Qualification Program Letter of Intent Process Under 21st Century Cures Act

Drug development teams preparing submissions under the Biomarker Qualification Program (BQP) will need to update their internal workflows: FDA has published a revised Letter of Intent Content Element Outline (February 2026) alongside an updated pre-LOI and debrief meeting request process, reshaping how requestors engage with the agency early in the Drug Development Tool qualification pathway.

The revisions apply to the Drug Development Tool (DDT) qualification process established under Section 507 of the 21st Century Cures Act of 2016. DDTs encompass biomarkers used for clinical trial enrichment, clinical outcome assessments (COAs) evaluating clinical benefit, and animal models supporting efficacy testing under the Animal Rule. Once a DDT achieves qualified status, it carries a defined context of use and can be referenced across IND, NDA, or BLA submissions without requiring FDA to re-evaluate its suitability on a program-by-program basis, reducing duplicative regulatory burden for sponsors.

The updated LOI Content Element Outline provides comprehensive preparation instructions for requestors entering the voluntary qualification pathway. Separately, the revised meeting request process governs both pre-LOI consultations and post-submission debrief sessions, which represent the primary structured touchpoints between requestors and CDER or CBER review staff before a formal qualification package is filed. Teams that submitted LOIs under the prior framework should verify alignment with the February 2026 outline before advancing to the next submission stage.

For regulatory affairs leads, the practical read centers on early engagement: the pre-LOI meeting mechanism exists specifically to surface scientific and evidentiary gaps before resource-intensive development work is committed. FDA's stated program objectives include encouraging collaborative consortia to share the qualification burden, a model that has gained traction in biomarker contexts where no single sponsor holds sufficient data to support a standalone submission. Qualified DDTs are catalogued in CDER and CBER's DDT Qualification Project Search database, providing visibility into active projects and already-qualified tools that may be applicable to programs in development.

The revised LOI outline and updated meeting request procedures are accessible through the Resources for Biomarker Requestors page on FDA.gov, with the DDT Qualification Project Search database available for locating existing qualified biomarkers and tracking project status.

Source: FDA Drugs RSS Feed via FDA.gov, 8 May 2026.